Palatin Technologies, Inc. (PTN)
Develops experimental drugs targeting melanocortin receptors to treat obesity, sexual dysfunction, and eye diseases.
$7.68-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-14.7%
The outlook
PTN is trading near the lower end of its 52-week range, well below both its 50- and 200-day moving averages, reflecting a bearish trend. Analyst coverage shows a wide gap, with the average price target implying substantial upside from current levels, though the stock carries a high trailing P/E of 69.8. The overall sentiment leans bearish despite the optimistic target positioning.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range10% of the way from its 52-week low to high
Price targetAvg target +597% vs current price
Analyst price target
~12-month · 3 analysts$53.50average target+596.6% vs now
Now $7.68
Low $47.50High $60.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$13.7M
52-wk high
$31.00
52-wk low
$5.00
50-day avg
$11.85
200-day avg
$15.75
Trailing P/E
69.8